Document:

Exhibit 10.7

 

Administrative Services Agreement

 

This Administrative Services Agreement (this “Agreement”)
entered into as of [●], 2022, by and between Alkaid Investments LLC (the “Provider”) and Alkaid Acquisition Corp. (the
“Company”).

 

The Provider has agreed to provide services to
the Company on the terms and conditions set out in this Agreement, and the Company is of the opinion that the Provider has the proper
and necessary qualifications, experience and abilities to provide services to the Company.

 

Therefore in consideration of the matters described
above, the receipt and sufficiency of which consideration is hereby acknowledged, the Company and the Provider agree as follows:

 

	1.	Scope of Work

 

The Provider is to provide the Company
with the following services (the “Services”): general and administrative services, including office space, utilities, secretarial
and administrative support services, as may be reasonably required by the Company from time to time, situated at 42 Broadway, 12th Floor,
New York, NY 10004 (or any successor location).

 

The Services will include any other
tasks which the Company and the Provider may agree on.

 

	2.	Term of Agreement

 

This Agreement will begin on the date
hereof and will remain in full force and effect until the earlier of the consummation by the Company of an initial business combination
or the Company’s liquidation (in each case as described in the Registration Statement for the Company’s initial public offering
(the “IPO”)) unless terminated earlier pursuant to the terms hereof. This Agreement may be extended by mutual written agreement
of the parties.

 

	3.	Trust Waiver

 

The Provider hereby agrees that it
does not have any right, title, interest or claim of any kind in or to any monies that may be set aside in a trust account (the “Trust
Account”) that may be established by the Company for the benefit of the Company’s public stockholders upon the consummation
of the IPO as described in the Registration Statement (“Claim”) and hereby waives any Claim it may have in the future as a
result of, or arising out of, any negotiations, contracts or agreements with the Company in connection with this Agreement and will not
seek recourse against the Trust Account for any reason whatsoever.

 

	4.	Termination 

 

If either party seeks termination of
this Agreement, the terminating party must provide a written notice to the other party.

 

	5.	Compensation 

 

The Company will provide compensation
to the Provider of $10,000 per month for the Services rendered by the Provider as required by this Agreement. The Provider agrees that
payment of such amounts may be deferred, without interest, until the date of consummation of the Company’s initial business combination
upon a determination by the Company’s audit committee that the Company lacks sufficient funds held outside the Trust Account to
pay the Company’s actual or anticipated expenses in connection with the Company’s initial business combination.

 

[signature page follows]

 

     

     

    

 

IN WITNESS WHEREOF the parties have duly executed
this Agreement as of the date first above written.

 

	 	ALKAID INVESTMENTS LLC

 

	 	By:	 
	 	Name: 	Min Gan
	 	Title:	Authorized Representative
	 	 	 
	 	ALKAID ACQUISITION CORP.

 

	 	By:	 
	 	Name: 	Greig Andrew Robert Charlton
	 	Title:	Chief Executive Officer

 

Signature Page to Administrative Services AgreementExhibit 10.1
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE
TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL
​

FIRST AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT
This FIRST AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT (this “Amendment”), entered into as of August 15, 2022 (the “Amendment Date”), is made and entered into by and between CStone Pharmaceuticals, a corporation organized and existing under the laws of the Cayman Islands, with a registered address at P.O. Box 31119, Grand Pavilion, Hibiscus Way, 802 West Bay Road, Grand Cayman, KY1-1205, Cayman Islands (“Licensor”) and EQRX INTERNATIONAL, INC., a Delaware corporation having its principal place of business at 50 Hampshire St., Cambridge, MA 02141 (“EQRx”). 
WHEREAS, Licensor and EQRx, Inc. entered into that certain Exclusive License Agreement, dated as of October 26, 2020 (the “Original Effective Date”), by and between Licensor and EQRx, Inc. (the “License Agreement”), pursuant to which Licensor granted to EQRx, Inc. a license, under the Licensor Licensed Technology, to permit EQRx to Develop and Commercialize the Licensed Antibodies and Licensed Products in the Territory, in accordance with the terms and conditions set forth therein; 
WHEREAS, EQRx, Inc. changed its name to EQRx International, Inc. as of December 16, 2021; 
WHEREAS, all Existing Patents were listed on Schedule 10.2(d) (Existing Patents) of the License Agreement;
WHEREAS, Licensor and EQRx acknowledge and agree that the Existing Patents are as set forth on Exhibit A as attached hereto and wish to amend Schedule 10.2(d) (Existing Patents) of the License Agreement by replacing it with Exhibit A as attached hereto; and
WHEREAS, the terms of the License Agreement may be modified by a written instrument, which is signed by an authorized officer of Licensor and EQRx pursuant to Section 16.1 thereof; 
NOW, THEREFORE, in consideration of the mutual covenants and obligations set forth in this Amendment and other good and valuable consideration, the sufficiency of which are hereby acknowledged, Licensor and EQRx agree as follows:  
1.Schedule 10.2(d) (Existing Patents) of the License Agreement shall be amended by replacing Schedule 10.2(d) (Existing Patents) in its entirety with Exhibit A attached hereto. 
​
2.Licensor and EQRx acknowledge, agree, memorialize and ratify, that the Existing Patents shall be as set forth as Exhibit A attached hereto as of the Original Effective Date.
​

1
​

3.The replacement of Schedule 10.2(d) with Exhibit A attached hereto will [***] on Schedule 10.2(d) (Existing Patents) of the License Agreement prior to the Amendment Date. 
​
4.Upon execution, this Amendment shall be made a part of the License Agreement and shall be incorporated by reference therein.
​
5.This Amendment may be executed in one (1) or more counterparts, each of which will be deemed an original, but all of which together will constitute one and the same instrument.
​
6.All provisions of the License Agreement not expressly modified by this Amendment shall remain in full force and effect. In the event of any conflict between the terms of the License Agreement and this Amendment, the terms of this Amendment shall govern and control.
​
7.This Amendment shall be governed by, and enforced and construed in accordance with, the laws of the State of New York, without regard to its conflicts of law provisions.
 ​
8.All capitalized terms used, but not otherwise defined herein, shall have the meanings ascribed to them in the License Agreement.

(Signature page follows)

2
​

​

IN WITNESS WHEREOF, the Parties have executed this Amendment by their duly authorized representatives as of the Amendment Date.
	CSTONE PHARMACEUTICALS
	EQRX INTERNATIONAL, INC.

	By:  /s/ Michael J. Choi
	By:  /s/ Melanie Nallicheri

	Name:  Michael J. Choi
	Name:  Melanie Nallicheri

	Title:  Chief Business Officer
August 15, 2022
	Title:  President & CEO 
8/11/2022

​
​
​
​
​
​
​
​
​
​
​
​
​
​
​
​
​
​

​

​

Exhibit A
SCHEDULE 10.2(d)
EXISTING PATENTS
[***] 

​Exhibit 10.2
​
CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE
TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL
​
​

FIRST AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT
This FIRST AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT (this “Amendment”) is entered into as of September 14, 2022 (the “Amendment Date”), between EQRx International, Inc. (formerly EQRx, Inc.), a Delaware corporation, having a place of business at 50 Hampshire St., Cambridge, MA 02139 USA (“EQRx”) and Lynk Pharmaceuticals (Hangzhou) Co., Ltd (a.k.a. Lynk Pharmaceutical (Hangzhou) Co., Ltd and Lynk Pharmaceuticals Co., Ltd.), a Chinese corporation, having a place of business at 291 Fucheng Road, Bldg. 5-402, Jiangan, Hangzhou, Zhejiang 310018, China (“Lynk”).  EQRx and Lynk are each referred to as a “Party” here and collectively, “Parties”.
WHEREAS, the Parties entered into an Exclusive License Agreement, dated April 1, 2020 (the “License Agreement”).
WHEREAS, pursuant to Section 4.6 of the License Agreement, the Parties agreed to: (i) collaborate on the research and development of formulation, process chemistry, and nonclinical studies for the Licensed Compounds and Licensed Products, (ii) agree on the terms and conditions thereof, including establishing a development plan [***], (iii) allocate the costs incurred by each Party associated with such activities[***] and (iv) reflect such terms and conditions in a written amendment to the License Agreement; and  
WHEREAS, the Parties intend to enter into this Amendment as contemplated by clause (iv) of the preceding sentence.
NOW, THEREFORE, in consideration of the mutual covenants and obligations set forth in this Amendment and other good and valuable consideration, the sufficiency of which are hereby acknowledged, the Parties hereby agree as follows:  
1.Cost Sharing Pursuant to Section 4.6.  The Parties hereby agree that the responsibility of the costs related to the research and development of [***] for the Licensed Compounds and Licensed Products (collectively, the “Allocable Costs”) for the time period from [***] through and including [***] will be allocated between the Parties as set forth on Schedule 1 hereto. 

Each Party will, to the extent not provided prior to the Amendment Date, [***] provide the other Party with [***] the costs and activities set forth on Schedule 1.  The Parties acknowledge and agree that, based on Schedule 1, [***] owes [***] a net payment of [***], and [***] shall pay such amount to [***] within [***] following the Amendment Date. 
Within [***] (or such other time period as agreed by the Parties) after the end of each [***], each Party shall provide the other Party the Allocable Costs incurred by such Party and [***] requested by the other Party, including invoices and purchase orders.  The Allocable Costs shall be shared by the Parties [***]. The JSC shall review and approve such Allocable Costs unless otherwise agreed to by the Parties in writing. The Party owing the net payment will pay the other Party within [***] following the JSC approval or such written agreement, as applicable.
​
		2.	Miscellaneous.

a.All terms and provisions of the License Agreement not expressly modified by this Amendment will remain in full force and effect. In the event of any conflict between the terms of the 

​

​

License Agreement and the terms of this Amendment, the terms of this Amendment shall govern and control.  For the avoidance of doubt, in the event of any dispute arising under this Amendment or any future Allocable Costs, the provisions in Article 12 of the License Agreement shall apply.
b.This Amendment will not be construed as an amendment to or waiver of any other provision of the License Agreement or as a waiver of or consent to any further or future action on the part of either Party that would require the waiver or consent of the other Party. 
c.This Amendment is governed by, and enforced and construed in accordance with, the laws of the State of New York, without regard to its conflicts of law provisions.
d.This Amendment may be executed in one (1) or more counterparts, each of which will be deemed an original, but all of which together constitute one and the same instrument. 
e. Any capitalized terms used and not defined in this Amendment have the respective meanings assigned to them in the License Agreement.
[SIGNATURE PAGE FOLLOWS]
​
​

2
​

​

IN WITNESS WHEREOF, the Parties have executed this Amendment by their duly authorized representatives as of the Amendment Date.
​
LYNK PHARMACEUTICALS (HANGZHOU) CO., LTD
​
By: [***]​ ​
Name: [***]​ ​
Title: [***]​ ​
 ​
​
​
EQRx INTERNATIONAL, INC. 
​
By: [***]​ ​
Name: [***]​ ​​ ​​ ​
Title: [***]​ ​
​

​

​

Schedule 1
[***]

​

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00350-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00350-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00350-of-00352.parquet"}]]